Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Proprietary Optejet Microdosing System: Eyenovia's unique Optejet dispenser delivers precise, micro-volume topical ophthalmic medications, minimizing waste and improving drug delivery to the eye.
Enhanced Patient Comfort and Compliance: The microdosing technology reduces solution overflow and potential systemic absorption, leading to less stinging, better tolerability, and improved adherence to treatment regimens.
Unique FDA-Approved Mydcombi Product: Mydcombi is the first and only fixed-dose combination of tropicamide and phenylephrine for pupil dilation, offering a convenient and efficient solution for ophthalmologists.
Risks
Mydcombi Commercialization Risks: The successful launch and market adoption of Mydcombi is uncertain, facing competition and challenges in physician acceptance and payer coverage.
Clinical Development and Approval Failures: Future product candidates, such as MicroLine for presbyopia, may fail to achieve positive results in clinical trials or face delays, preventing regulatory approval.
Need for Additional Capital: Eyenovia has a history of losses and will require significant additional funding to commercialize Mydcombi and advance its pipeline, which may not be available on favorable terms.
Monday
Over a week ago
May 6, 8:07 AM
May 5, 4:08 PM
Mar 24, 8:13 AM
Mar 9, 8:12 AM
Feb 4, 8:16 AM
Jan 12, 8:37 AM
Jan 5, 8:12 AM
Dec 24, 4:30 AM
Dec 16, 6:41 AM
Dec 4, 8:04 AM
Nov 17, 8:03 AM
Oct 29, 8:03 AM
Sep 29, 8:11 AM
Sep 25, 8:04 AM